HKUB-006

HKUB-006 is a gene therapy candidate currently in the discovery phase, developed by Hong Kong Universal Biologicals (HKUBio) for the treatment of chronic obstructive pulmonary disease (COPD). The therapeutic utilizes the company's proprietary Innovative Viral Vector Platform, which is engineered to deliver genetic payloads directly to the respiratory system. HKUBio, a spinoff from the University of Hong Kong, leverages advanced viral vector technologies—often based on influenza or other respiratory virus backbones—to address unmet needs in pulmonary medicine. While the specific transgene or molecular target for HKUB-006 has not been publicly disclosed, the program aims to modify the disease course of COPD through localized gene expression in the respiratory tract.